(Q34373489)

1 August 2017

Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia (English)

1 reference

1 August 2017

0 references

J A Den Boer

1

1 reference

1 August 2017

H J van Megen

2

1 reference

1 August 2017

W W Fleischhacker

3

1 reference

1 August 2017

J W Louwerens

4

1 reference

1 August 2017

B R Slaap

5

1 reference

1 August 2017

H G Westenberg

6

1 reference

1 August 2017

G D Burrows

7

1 reference

1 August 2017

O N Srivastava

8

1 reference

1 August 2017

1 October 1995

1 reference

1 August 2017

6

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

1 August 2017

121

1 reference

1 August 2017

317-322

1 reference

1 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/bf02246069

1 August 2017

0 references

cites work

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02246069

Binding of [3H]SCH 39166 to human post mortem brain tissue.

21 January 2018

1 reference

12 December 2020

Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors

1 reference

12 December 2020

Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists

1 reference

12 December 2020

Schizophrenia and the D1 receptor: focus on negative symptoms

1 reference

12 December 2020

The effects of haloperidol and raclopride in the paw test are influenced similarly by SCH 39166

1 reference

12 December 2020

In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity

1 reference

12 December 2020

The psychogenic effects of prolactin

1 reference

12 December 2020

Dopamine receptors and the dopamine hypothesis of schizophrenia

1 reference

12 December 2020

The positive-negative dimension in schizophrenia: its validity and significance.

1 reference

12 December 2020

Reliability and validity of the positive and negative syndrome scale for schizophrenics

1 reference

12 December 2020

Are antagonists of dopamine D1 receptors drugs that attenuate both positive and negative symptoms of schizophrenia? A pilot study in Java monkeys

1 reference

12 December 2020

Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

1 reference

12 December 2020

Evidence that stimulatory dopamine receptors may be involved in the regulation of prolactin secretion

1 reference

12 December 2020

PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.

1 reference

12 December 2020

Neurons in the hypothalamic paraventricular nucleus mediate the serotonergic stimulation of prolactin secretion via 5-HT1c/2 receptors.

1 reference

12 December 2020

Management of psychotropic-induced hyperprolactinemia

1 reference

12 December 2020

Lack of acute antipsychotic effect of Sch 23390, a selective dopamine D1 receptor antagonist

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02246069

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference